References
- 1. MacCallum C, Russo E. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 2018;49:12-9. doi: 10.1016/j.ejim.2018.01.00410.1016/j.ejim.2018.01.004
- 2. Lucić Vrdoljak A, Fuchs N, Mikolić A, Žunec S, Brčić Karačonji I, Jurič A, Prester L, Micek V, Neuberg M, Čanović S, Mršić G, Kopjar N. Irinotecan and ∆9-tetrahydrocannabinol interactions in rat liver: a preliminary evaluation using biochemical and genotoxicity markers. Molecules 2018;23:1332. doi: 10.3390/molecules2306133210.3390/23061332
- 3. Atakan Z. Cannabis, a complex plant: Different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012;2:241-54. doi: 10.1177/204512531245758610.1177/2045125312457586
- 4. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 2009;105:24-32. doi: 10.1016/j.drugalcdep.2009.05.02710.1016/j.drugalcdep.2009.05.027
- 5. Đorđević S, Krstić N, Kilibarda V, Šulić K, Jovanović B. Prikaz metoda za dokazivanje i određivanje kanabinoida u biološkom materijalu [A review of methods for determination of cannabinoids in biological samples, in Serbian]. Med Rev 2011;3:063-8.
- 6. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 2006;28:155-63. doi: 10.1097/01.ftd.0000197091.07807.2210.1097/01.ftd.0000197091.07807.22
- 7. Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther 2003;3:3-51. doi: 10.1300/J175v03n01_0210.1300/J175v03n01_02
- 8. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC–EI-MS determination of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007;31:477-85. doi: 10.1093/jat/31.8.47710.1093/jat/31.8.477
- 9. Brenneisen R, Meyer P, Chtioui H, Saugy M, Kamber M. Plasma and urine profiles of Δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem 2010;396:2493-502. doi: 10.1007/s00216-009-3431-310.1007/s00216-009-3431-3
- 10. Weinmann W, Vogt S, Goerke R, Muller C, Bromberger A. Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS. Forensic Sci Int 2000;113:381-7. doi: 10.1016/S0379-0738(00)00210-3
- 11. Felli M, Martello S, Chiarotti M. LC-MS-MS method for simultaneous determination of THCCOOH and THCCOOH-glucuronide in urine: Application to workplace confirmation tests. Forensic Sci Int 2011;204:67-73. doi: 10.1016/j.forsciint.2010.05.00410.1016/j.forsciint.2010.05.004
- 12. Schaefer N, Kettner M, Laschke MW, Schlote J, Peters B, Bregel D, Menger MD, Maurer HH, Ewald AH, Schmidt PH. Simultaneous LC-MS/MS determination of JWH-210, RCS-4, ∆(9)-tetrahydrocannabinol, and their main metabolites in pig and human serum, whole blood, and urine for comparing pharmacokinetic data. Anal Bioanal Chem 2015;407:3775-86. doi: 10.1007/s00216-015-8605-610.1007/s00216-015-8605-6
- 13. Teixeira H, Verstraete A, Proença P, Corte-Real F, Monsanto P, Vieira DN. Validated method for the simultaneous determination of Δ9-THC and Δ9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci Int 2007;170:148-55. doi: 10.1016/j.forsciint.2007.03.02610.1016/j.forsciint.2007.03.026
- 14. Battista N, Sergi M, Montesano C, Napoletano S, Compagnone D, Maccarrone M. Analytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices. Drug Test Anal 2014;6:7-16. doi: 10.1002/dta.157410.1002/dta.1574
- 15. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the conentration of THC and two metabolites in urine. J Anal Toxicol 1995;19:292-8. doi: 10.1093/jat/19.5.292
- 16. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 2009;36:580–90. doi:10.1016/j.ejps.2008.12.005.10.1016/j.ejps.2008.12.005
- 17. Böhmdorfer M, Maier-Salamon A, Riha J, Brenner S, Höferl M, Jäger W. Interplay of drug metabolizing enzymes with cellular transporters. Wien Med Wochenschr 2014;164:461-71. doi: 10.1007/s10354-014-0301-110.1007/s10354-014-0301-1
- 18. Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 2002;19:1345-53. doi: 10.1023/A:102035891049010.1023/A:1020358910490
- 19. Li C, Li X, Choi J. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats. Arch Pharm Res 2009;32:133-8. doi: 10.1007/s12272-009-1127-z
- 20. Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, Ryuge S, Wada M, Onoda S, Yanaihara T, Yokoba M, Mitsufuji H, Nishii Y, Fukui T, Masuda N. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 2008;20:727-30. doi: 10.3892/or_0000006610.3892/or_00000066
- 21. Karačić V, Skender Lj. Analysis of drugs of abuse in urine by gas chromatography/mass spectrometry: Experience and application. Arh Hig Rada Toksikol 2000;51:389-400. PMID: 11276966
- 22. Jung J, Meyer MR, Maurer HH, Neusüß C, Weinmann W, Auwärter V. Studies on the metabolism of the Δ9-tetrahydrocannabinol precursor Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in rat using LC-MS/MS, LC-QTOFMS and GC-MS techniques. J Mass Spectrom 2007;44:1423-33. doi: 10.1002/jms.162410.1002/jms.1624
- 23. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875-94. doi: 10.1517/17425255.2.6.87510.1517/17425255.2.6.875
- 24. Coskun ZM, Bolkent S. Evaluation of Δ9-tetrahydrocannabinol metabolites and oxidative stress in type 2 diabetic rats. Iran J Basic Med Sci 2016;19:154-8. PMCID: PMC4818362
- 25. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20. PMID: 10815927
- 26. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 2009;37:1496-504. doi: 10.1124/dmd.109.02689810.1124/dmd.109.026898